Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 35Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 23Papillomavirus Vaccines 14Data Collection 7Blood Specimen Collection 7Vaccines 6Vaccines, Synthetic 5Educational Status 5Radiotherapy, Intensity-Modulated 4Human Papillomavirus Recombinant Vaccine nonavalent 4Early Intervention, Educational 4Vaginal Smears 3Surveys and Questionnaires 3Polymerase Chain Reaction 3Paclitaxel 3Methods 3Engerix-B 3Colposcopy 3Cisplatin 3halofantrine 2fludarabine phosphate 2fludarabine 2aldesleukin 2Watchful Waiting 2Taxes 2Patient Navigation 2Papanicolaou Test 2Observation 2Light Coagulation 2Imiquimod 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Papillomavirus Infections × Doxylamine × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡